ReviewHeart failure reviews2022
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial.Cardiovascular diabetology · 2023Trial
- Commentary on the Prognostic Interpretation of the Triglyceride-Glucose Index in Patients with HCM and HFpEF.Anatolian journal of cardiology · 2026Article
- Variant burden and severity of cardiomyopathy in patients with DMD-related Duchenne muscular dystrophy.Pediatric research · 2026Article
- Clinical effects of sodium-glucose cotransporter 2 inhibitors combined with conventional therapy in myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2026Review
- The use of SGLT2 inhibitors in older people: What is important?Aging clinical and experimental research · 2025Review
- CD36 attenuates pressure overload-induced myocardial insulin resistance via HSF1-dependent HSP90α suppression and competitive disruption of the HSP90α-InsR complex.Journal of translational medicine · 2025Article
- Stress Hyperglycemia Ratio Outperforms Glycemic Variability in Predicting Mortality Among Acute Myocardial Infarction Patients With Reduced Ejection Fraction: A Retrospective Cohort Study.Journal of diabetes · 2025Article
- The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?Cardiovascular diabetology · 2025Review
- Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.International journal of molecular sciences · 2025Review
- Sodium-glucose cotransporter-1 inhibition and depression: A Mendelian randomization study.SAGE open medicine · 2025Article
- Association between triglyceride-glucose index and the risk of heart failure hospitalization in older diabetic patients received right ventricular pacing: a retrospective cohort study.Acta diabetologica · 2024Article
- Association Between Different Insulin Resistance Indices and Heart Failure in US Adults With Diabetes Mellitus.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2024Article
- Metabolic score for insulin resistance as a predictor of mortality in heart failure with preserved ejection fraction: results from a multicenter cohort study.Diabetology & metabolic syndrome · 2024Article
- From Energy Metabolic Change to Precision Therapy: a Holistic View of Energy Metabolism in Heart Failure.Journal of cardiovascular translational research · 2024Review
- Immunomodulation and immunopharmacology in heart failure.Nature reviews. Cardiology · 2024Review
- The Relationship Between Insulin Resistance Indicated by Triglyceride and Glucose Index and Left Ventricular Hypertrophy and Decreased Left Ventricular Diastolic Function with Preserved Ejection Fraction.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance.Diabetes & metabolism journal · 2024Review
- A low-carbohydrate diet in place of SGLT2i therapy in a patient with diabetic cardiomyopathy.Endocrinology, diabetes & metabolism case reports · 2023Article
- High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction.Cardiovascular diabetology · 2023Article
- [Synergistic effects of GABA and hypoglycemic drugs].Problemy endokrinologii · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) often coexists with insulin resistance (IR), and the incidence of HF in type 2 diabetes mellitus (T2DM) patients is significantly higher. The reciprocal relationship between HF and IR has long been recognized, and the integration complicates the therapy of both. A number of mechanisms ascribe to the progression of cardiac IR, in which the main factors are the shift of myocardial substrate metabolism. Studies have found that SGLT2 inhibitors, an anti-diabetic drug, can improve the cardiac prognosis of patients with T2DM, which may be at least partially due to the relief of cardiac IR. Basic and clinical studies have revealed the important role of cardiac IR in the pathogenesis and progression of HF, and studies suggest that energy metabolism plays an important role in the pathogenesis of cardiac IR and HF. SGLT2 inhibitors mediated cardiovascular benefits through various mechanisms such as improving substrate utilization and improving myocardial energy. The regulation of SGLT2 inhibitors on cardiac energy status including carbohydrates, fatty acids (FA), amino acids and ketones, ATP transfer to the cytoplasm, and mitochondrial functional status have received extensive attention in HF, but its specific mechanism of action is still unclear. Therefore, this article reviews the relationship between IR and HF from the perspective of energy metabolism; subsequently, targeting energy metabolism discusses the pivotal role of SGLT2 inhibitors in improving cardiac IR and HF based on basic and clinical research evidences, and sought to clarify the molecular mechanism involved. (Fig. 1).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.